TG Therapeutics, Inc. $TGTX Holdings Trimmed by Clearbridge Investments LLC

Clearbridge Investments LLC reduced its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 25.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,448,033 shares of the biopharmaceutical company’s stock after selling 1,196,442 shares during the period. Clearbridge Investments LLC owned 2.17% of TG Therapeutics worth $102,786,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in shares of TG Therapeutics by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 898,409 shares of the biopharmaceutical company’s stock valued at $26,782,000 after acquiring an additional 25,858 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock valued at $61,144,000 after acquiring an additional 531,759 shares in the last quarter. Natixis Advisors LLC grew its holdings in shares of TG Therapeutics by 4.8% during the 4th quarter. Natixis Advisors LLC now owns 44,494 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,047 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of TG Therapeutics by 856.6% during the 4th quarter. BNP Paribas Financial Markets now owns 683,653 shares of the biopharmaceutical company’s stock valued at $20,380,000 after acquiring an additional 612,189 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in shares of TG Therapeutics by 116.0% during the 4th quarter. Intech Investment Management LLC now owns 153,132 shares of the biopharmaceutical company’s stock valued at $4,565,000 after acquiring an additional 82,253 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 2.0%

TGTX stock opened at $40.95 on Tuesday. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. TG Therapeutics, Inc. has a 1 year low of $25.28 and a 1 year high of $44.65. The company has a fifty day simple moving average of $37.23 and a 200 day simple moving average of $32.68. The firm has a market cap of $6.27 billion, a PE ratio of 14.32 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same period in the previous year, the firm posted $0.03 EPS. The firm’s revenue for the quarter was up 69.5% on a year-over-year basis. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 1.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. Finally, HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of TG Therapeutics in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $52.50.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.